Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population

Vaccine ◽  
2014 ◽  
Vol 32 (44) ◽  
pp. 5816-5823 ◽  
Author(s):  
Jacob Atsmon ◽  
Yoseph Caraco ◽  
Sagit Ziv-Sefer ◽  
Dimitry Shaikevich ◽  
Ester Abramov ◽  
...  
2017 ◽  
Vol 3 (4) ◽  
pp. 212
Author(s):  
Sukamto Koesnoe ◽  
Ummu Habibah ◽  
Edy Rizal Wahyudi ◽  
Murdani Abdullah

Pendahuluan. Infeksi masih merupakan ancaman yang serius bagi dunia kesehatan saat ini, terutama bagi populasi khusus seperti usia lanjut. Usia dinyatakan sebagai salah satu faktor prediktor dalam keberhasilan vaksinasi. Semakin tua usia seseorang, respon imunnya akan semakin buruk. Respon yang berbeda pada usia lanjut ini diperkirakan karena frailty dan kejadian immunosenescense yang mendasarinya. Penelitian ini dilakukan untuk mengetahui hubungan status frailty dengan respon imun pascavaksinasi influenza pada populasi usia lanjut.Metode. Studi kohort retrospektif ini mengambil data dari penelitian induk dengan subjek usia lanjut berusia ≥60 yang tergabung dalam Posyandu Lansia di 4 kelurahan di Kecamatan Pulo Gadung, Jakarta Timur. Status frailty ditentukan berdasarkan kuisoner Frailty Index 40 Items (FI-40). Vaksin Influenza yang dievaluasi adalah vaksin influenza trivalen inaktif. Serokonversi didefinisikan sebagai peningkatan titer inhibisi hemagglutinin sebanyak 4x lipat. Seroproteksi didefinisikan sebagai titer inhibisi hemagglutinin ≥1:40.Hasil. Terdapat 140 subjek penelitian. Tingkat serokonversi vaksin influenza pada kelompok frail, pre-frail dan sehat adalah 37,9%, 39% dan 60%. Tingkat seroproteksi vaksin influenza pada kelompok frail, pre-frail dan sehat adalah 80%, 92,2% dan 94,8% . Risiko relatif (RR) kelompok pre-frail/frail untuk kejadian tidak serokonversi adalah 0,93 (IK 95% 0,72-1,02) dan RR untuk kejadian tidak seroproteksi adalah 1,7 ( IK 95% 0,5-6,2).Simpulan. Tidak ditemukan hubungan antara status frailty dengan serokonversi dan seroproteksi vaksin influenza pada populasi usia lanjut.Kata Kunci: Frailty, pre-frail, frail, serokonversi, seroproteksi, usia lanjut, vaksin influenza  Correlation of Frailty Status with Influenza Vaccine Seroconversion and Seroprotection among Elderly PopulationIntroduction. Infection is still considered as a serious health threat in the world, especially among the elderly. Age was identified as one of the predictor factors for successfull vaccination. Immune response would decrease in older people. A different response in the elderly is expected from frailty and underlying immunosenescense events. This study was conducted to determine the relationship with the Frailty status after the vaccination immune response of influenza in the elderly population. Methods. This retrospective cohort study was conducted using secondary data from the parent study of elderly subjects age ≥60 years who live in the community of Posyandu lansia in Pulo Gadung Region, East Jakarta. Frailty status was stated by Frailty Index 40 Items (FI-40). The influenza vaccine evaluated was the Trivalent Inactivated Vaccine. Seroconversion defined as four fold increase hemagglutinin inhibition titre. Seroprotection defined as Hemagglutinin Inhibition titer ≥1:40. Results. There are 140 subject included in this study. Seroconversion influenza vaccine rate in frail, pre-frail, and robust group are 37.9%, 39%, 60%, respectively. Seroprotection rate in frail, pre-frail, and robust group are 80%, 92.2%, 94.8%, respectively. Relative Risk (RR) pre-frail/frail group for not seroconverted is 0.93 (CI 95% 0.72-1.02), and RR for not seroprotected is 1,7 ( CI 95% 0.5-6.2). Conclussions. There is no association between frailty status and seroconversion nor seroprotection of influenza vaccine in elderly population. Keywords: elderly, frail, influenza vaccine, pre-frail, seroconversion, seroprotection


Vaccine ◽  
2019 ◽  
Vol 37 (36) ◽  
pp. 5314-5322 ◽  
Author(s):  
Massimo Fabiani ◽  
Enrico Volpe ◽  
Maurizio Faraone ◽  
Antonino Bella ◽  
Caterina Rizzo ◽  
...  

2020 ◽  
Vol 19 (5) ◽  
pp. 479-489
Author(s):  
Massimo Fabiani ◽  
Enrico Volpe ◽  
Maurizio Faraone ◽  
Antonino Bella ◽  
Patrizio Pezzotti ◽  
...  

Author(s):  
Jiong Wang ◽  
Alexander Wiltse ◽  
Martin S. Zand

The human antibody response to influenza virus infection or vaccination is as complicated as it is essential for protection against flu. The constant antigenic changes of the virus to escape human herd immunity hinder the yearly selection of vaccine strains since it is hard to predict which virus strains will circulate for the coming flu season. A "universal" influenza vaccine that could induce broad cross-influenza subtype protection would help to alleviate this burden. However, the human antibody response is intricate and often obscure, with factors like antigenic seniority or original antigenic sin "OAS", and back-boosting ensuring that each person mounts a unique immune response to infection or vaccination with any new influenza virus strain. Notably, the effects of existing antibodies on cross-protective immunity after repeated vaccinations are unclear. More research is needed to characterize the mechanisms at play, but traditional assays such as hemagglutinin inhibition (HAI) and microneutralization (MN) are excessively limited in scope and too resource-intensive to effectively meet this challenge. In the past ten years, new multiple dimensional assays (MDAs) have been developed to help overcome these problems by simultaneously measuring antibodies against a large panel of influenza hemagglutinin (HA) proteins with a minimal amount of sample in a high throughput way. MDAs will likely be a powerful tool for accelerating the study of the humoral immune response to influenza vaccination and the development of a universal influenza vaccine.


Sign in / Sign up

Export Citation Format

Share Document